FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037665874> ?p ?o ?g. }

• W2037665874 endingPage "84" @default.
• W2037665874 startingPage "77" @default.
• W2037665874 abstract "To evaluate the safety and toxicity of peptide vaccination for patients with metastatic hormone-refractory prostate cancer (HRPC) based on pre-existing peptide-specific cytotoxic T-lymphocyte (CTL) precursors in the circulation, 10 patients positive for human leukocyte antigen (HLA)-A2 with metastatic HRPC were enrolled in a phase I study. Peptide-specific CTL-precursors reactive to 16 kinds of vaccine candidates in the pre-vaccination peripheral blood mononuclear cells (PBMCs) were measured, and patients were followed by vaccination with only positive peptides (up to 4 kinds of peptides). Serum prostate-specific antigen (PSA) levels were monitored regularly. The peptide vaccination was safe and well tolerated with no major adverse effects. The most common toxicities were dermatologic reactions at the injection site. Increased CTL response to peptides was observed in 4 of 10 patients. Anti-peptide IgG was also detected in post-vaccination sera of 7 of 10 patients. One patient showed the disappearance of a pelvic bone metastasis after five vaccinations. Three patients showed a decrease of serum PSA level from the baseline after the vaccination, but no patients showed a serum PSA level decrease of >/= 50%. The median survival duration of study patients was 22 months with follow-up from 3 to 27 months. We consider that the increase in cellular and humoral immune responses, and decrease in PSA level in some patients justify further development of peptide vaccination for metastatic HRPC patients." @default.
• W2037665874 created "2016-06-24" @default.
• W2037665874 creator A5006133126 @default.
• W2037665874 creator A5019290673 @default.
• W2037665874 creator A5034428180 @default.
• W2037665874 creator A5034924637 @default.
• W2037665874 creator A5036887208 @default.
• W2037665874 creator A5044424550 @default.
• W2037665874 creator A5050204003 @default.
• W2037665874 creator A5070720566 @default.
• W2037665874 creator A5074736988 @default.
• W2037665874 date "2004-01-01" @default.
• W2037665874 modified "2023-10-12" @default.
• W2037665874 title "Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer" @default.
• W2037665874 cites W1868723949 @default.
• W2037665874 cites W1970735557 @default.
• W2037665874 cites W1983806918 @default.
• W2037665874 cites W1984873560 @default.
• W2037665874 cites W1987387600 @default.
• W2037665874 cites W2006219146 @default.
• W2037665874 cites W2006987944 @default.
• W2037665874 cites W2009529714 @default.
• W2037665874 cites W2019653601 @default.
• W2037665874 cites W2026763255 @default.
• W2037665874 cites W2031744617 @default.
• W2037665874 cites W2033174123 @default.
• W2037665874 cites W2053531118 @default.
• W2037665874 cites W2066440404 @default.
• W2037665874 cites W2080645865 @default.
• W2037665874 cites W2083431758 @default.
• W2037665874 cites W2106263242 @default.
• W2037665874 cites W2124129321 @default.
• W2037665874 cites W2130185552 @default.
• W2037665874 cites W2155679349 @default.
• W2037665874 cites W2329334730 @default.
• W2037665874 cites W4238038733 @default.
• W2037665874 doi "https://doi.org/10.1111/j.1349-7006.2004.tb03174.x" @default.
• W2037665874 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14720331" @default.
• W2037665874 hasPublicationYear "2004" @default.
• W2037665874 type Work @default.
• W2037665874 sameAs 2037665874 @default.
• W2037665874 citedByCount "34" @default.
• W2037665874 countsByYear W20376658742012 @default.
• W2037665874 countsByYear W20376658742013 @default.
• W2037665874 countsByYear W20376658742016 @default.
• W2037665874 countsByYear W20376658742017 @default.
• W2037665874 countsByYear W20376658742023 @default.
• W2037665874 crossrefType "journal-article" @default.
• W2037665874 hasAuthorship W2037665874A5006133126 @default.
• W2037665874 hasAuthorship W2037665874A5019290673 @default.
• W2037665874 hasAuthorship W2037665874A5034428180 @default.
• W2037665874 hasAuthorship W2037665874A5034924637 @default.
• W2037665874 hasAuthorship W2037665874A5036887208 @default.
• W2037665874 hasAuthorship W2037665874A5044424550 @default.
• W2037665874 hasAuthorship W2037665874A5050204003 @default.
• W2037665874 hasAuthorship W2037665874A5070720566 @default.
• W2037665874 hasAuthorship W2037665874A5074736988 @default.
• W2037665874 hasBestOaLocation W20376658741 @default.
• W2037665874 hasConcept C121608353 @default.
• W2037665874 hasConcept C126322002 @default.
• W2037665874 hasConcept C137061746 @default.
• W2037665874 hasConcept C143998085 @default.
• W2037665874 hasConcept C147483822 @default.
• W2037665874 hasConcept C147969180 @default.
• W2037665874 hasConcept C154317977 @default.
• W2037665874 hasConcept C167672396 @default.
• W2037665874 hasConcept C195616568 @default.
• W2037665874 hasConcept C197934379 @default.
• W2037665874 hasConcept C202751555 @default.
• W2037665874 hasConcept C203014093 @default.
• W2037665874 hasConcept C22070199 @default.
• W2037665874 hasConcept C2776789287 @default.
• W2037665874 hasConcept C2780192828 @default.
• W2037665874 hasConcept C55493867 @default.
• W2037665874 hasConcept C71924100 @default.
• W2037665874 hasConcept C86803240 @default.
• W2037665874 hasConcept C8891405 @default.
• W2037665874 hasConcept C90924648 @default.
• W2037665874 hasConceptScore W2037665874C121608353 @default.
• W2037665874 hasConceptScore W2037665874C126322002 @default.
• W2037665874 hasConceptScore W2037665874C137061746 @default.
• W2037665874 hasConceptScore W2037665874C143998085 @default.
• W2037665874 hasConceptScore W2037665874C147483822 @default.
• W2037665874 hasConceptScore W2037665874C147969180 @default.
• W2037665874 hasConceptScore W2037665874C154317977 @default.
• W2037665874 hasConceptScore W2037665874C167672396 @default.
• W2037665874 hasConceptScore W2037665874C195616568 @default.
• W2037665874 hasConceptScore W2037665874C197934379 @default.
• W2037665874 hasConceptScore W2037665874C202751555 @default.
• W2037665874 hasConceptScore W2037665874C203014093 @default.
• W2037665874 hasConceptScore W2037665874C22070199 @default.
• W2037665874 hasConceptScore W2037665874C2776789287 @default.
• W2037665874 hasConceptScore W2037665874C2780192828 @default.
• W2037665874 hasConceptScore W2037665874C55493867 @default.
• W2037665874 hasConceptScore W2037665874C71924100 @default.
• W2037665874 hasConceptScore W2037665874C86803240 @default.
• W2037665874 hasConceptScore W2037665874C8891405 @default.
• W2037665874 hasConceptScore W2037665874C90924648 @default.

• next